BioLineRx (NASDAQ:BLRX) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price objective on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

BioLineRx Trading Up 3.5 %

BLRX opened at $0.30 on Monday. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.49. BioLineRx has a fifty-two week low of $0.25 and a fifty-two week high of $1.89. The company’s 50 day moving average price is $0.45 and its two-hundred day moving average price is $0.60. The firm has a market capitalization of $23.74 million, a price-to-earnings ratio of -1.35 and a beta of 1.48.

Hedge Funds Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. PVG Asset Management Corp acquired a new position in BioLineRx in the second quarter valued at $70,000. Atria Investments Inc raised its position in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares in the last quarter. Finally, CVI Holdings LLC bought a new position in shares of BioLineRx in the 2nd quarter worth about $462,000. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.